This week in techniques

Approach	Summary	Licensing status	Publication and contact information
Markers			
A truncated form of chemokine CXC motif ligand 10 (CXCL10; IP-10) as a marker for nonresponsiveness to HCV therapy	<p>Studies in patients suggest that plasma levels of a truncated form of CXCL10 could help identify nonresponders to HCV therapy. In HCV patients receiving standard therapy of interferon plus ribavirin, nonresponders had higher plasma levels of a truncated form of CXCL10 and greater total CXCL10 levels than responders ($p=0.04$ and $p=0.01$, respectively). Next steps include a validation study using additional patient samples.</p> <p>Rules-Based Medicine Inc., which uses its Multi-Analyte Profiling (MAP) technology platform to detect and analyze biomarkers, has rights to the findings.</p> <p>SciBX 4(3); doi:10.1038/scibx.2011.90 Published online Jan. 20, 2011</p>	Multiple patents covering use of NH_2 -truncated CXCL10 as a predictor for HCV as well as other chronic inflammatory diseases; licensed to Rules-Based Medicine	<p>Casrouge, A. <i>et al. J. Clin. Invest.</i>; published online Dec. 22, 2010; doi:10.1172/JCI40594</p> <p>Contact: Matthew L. Albert, Pasteur Institute, Paris, France e-mail: albertm@pasteur.fr</p>